PBPK Modeling Approach in Pregnant Subjects and Fetus

Webinar: Wednesday, September 29th


5 PM CEST (Paris) / 8 AM PDT (Los Angeles) / 11 AM EDT (New York)



Maxime Le Merdy



Learn More! simulations-plus.com/events



Guidance for Industry

Pharmacokinetics in Pregnancy — Study Design, Data Analysis, and Impact on Dosing and Labeling

FDA, 2004

"Introduction to population PK modeling approaches" "PK studies including pregnant patients, **physiological changes** during and after pregnancy **that are critical for drug absorption and disposition** may need to be considered in the model." Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials Guidance for Industry

FDA, 2018

EMA, 2006

GUIDELINE ON

THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY:

NEED FOR POST-AUTHORISATION DATA

GUIDELINE ON RISK ASSESSMENT OF MEDICINAL PRODUCTS ON HUMAN REPRODUCTION AND LACTATION: FROM DATA TO LABELLING



EMA, 2009

Pregnant women clinical information

<u>Clinical Trials</u>

- Safe
- Ethical if the drug provides a direct benefit to either the mom or the fetus

Post-marketing

- Safety concerns
- Ethical limitations
- Other approaches are necessary



Paracetamol

Paracetamol is considered safe to use at all stages of pregnancy by physicians and pharmacist

... and yet:

OPEN

Check for updates


Paracetamol use during pregnancy — a call for precautionary action

Ann Z. Bauer¹, Shanna H. Swan², David Kriebel¹, Zeyan Liew³, Hugh S. Taylor⁴, Carl-Gustaf Bornehag^{2,5}, Anderson M. Andrade⁶, Jørn Ols**e**n⁷, Rigmor H. Jensen⁶, Rod T. Mitchell⁹, Niels E. Skakkebaek¹⁰, Bernard Jégou^{11,13} and David M. Kristensen^{8,11,12}

https://www.nature.com/articles/s41574-021-00553-7.pdf



Paracetamol



"We recommend that APAP should be used by pregnant women cautiously at the lowest effective dose for the shortest possible time. Long-term or high-dose use should be limited to indications as advised by a

health professional."

APAP = Paracetamol

S+ SimulationsPlus


SCIENCE + SOFTWARE = SUCCESS

https://www.nature.com/articles/s41574-021-00553-7.pdf

"For PK studies including pregnant patients, physiological changes during and after pregnancy that are critical for drug absorption and disposition may need to be considered in the model."

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokineticspregnancy-study-design-data-analysis-and-impact-dosing-and-labeling






S# SimulationsPlus


SCIENCE + SOFTWARE = SUCCESS


Fetal PBPK Model



S SimulationsPlus

Fetal PBPK Model





S + Simulations Plus science + software = success

Maternal – Fetal Exchange

SimulationsPlus

DFTWARE = SUCCESS

Intramembranous pathway

rapid movement of water and solute that occurs between
amniotic fluid and fetal blood within the placenta and membranes
→ Disappears after skin keratinization (GA 20)


Transmembraneous pathway


movement of water and solute between amniotic fluid and maternal blood within the wall of the uterus
→ Important in early gestation

Fetal pathway

Movement of water and solute between amniotic fluid and fetal organs

→ Starts between the 9th and 12th GA





GastroPlus Demo



Case study 1 API eliminated solely by the kidney



S + SimulationsPlus science + software = success

Model development and validation




Model adjustments Postpartum



Pregnancy prediction








- CFX is cleared by renal filtration and active secretion
- All tissues defined as perfusion limited except the kidney
- Kidney secretion mediated by OAT3 and MRP4. Vmax parameters were fitted

→ PBPK model can reasonably described the observed concentration following IV administration at 3 doses



S + Simulations Plus science + software = success




 Transporters Vmax parameters were adjusted to capture the urinary excretion data

→ PBPK model can reasonably described the observed concentration following IV administration in Postpartum subject








Placenta model was changed to permeability limited

➔ PBPK model can reasonably described the observed maternal and fetal concentrations following IV administration




St Simulations Plus Science + Software = Success









200

Case study 2 API eliminated solely by the liver



SI Simulations Plus

Model development and validation




Model adjustments Postpartum



Pregnancy prediction








- MTD is metabolized by the CYPs 3A4, 2A6, 2E1 and UGT
- All tissues defined as perfusion limited

 PBPK model can reasonably described the observed concentration following IV/PO administrations.








 No model adjustment was made based on Postpartum data at 2 doses (0.25/1g PO)

 → PBPK model can reasonably described the observed concentration following PO administration in Postpartum subject.








→ PBPK model can reasonably described the observed maternal Cp-time concentrations following PO administration at different stages of pregnancy







200

Summary

- Ethics and safety concerns exist for Pregnant populations
- Pregnancy PBPK models can predict maternal and fetal PK/exposure
- Postpartum data may be interesting to calibrate the PBPK model
- Placenta model structure is probably dependent of the molecule of interest





To Learn More

The AAPS Journal (2021) 23:89 DOI: 10.1208/s12248-021-00603-y



Research Article

Theme: Celebrating Women in the Pharmaceutical Sciences Guest Editors: Diane Burgess, Marilyn Morris and Meena Subramanyam

PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus

Ke Xu Szeto,¹ Maxime Le Merdy,¹ Benjamin Dupont,² Michael B. Bolger,¹ and Viera Lukacova^{1,3}

Received 22 December 2020; accepted 27 April 2021



Acknowledgment

- Dr. Ke Xu Szeto
- Dr. Benjamin Dupont
- Dr. Haiying Zhou
- Dr. Viera Lukacova
- Dr. Michael B. Bolger







GastroPlus® 9.8 For More Information:

Visit our website at: www.simulations-plus.com

Or info@simulations-plus.com

Thank you and see you during the following workshops!



